Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Raw Materials (2019 - 2025)

IGC Pharma (IGC) has disclosed Raw Materials for 7 consecutive years, with $446000.0 as the latest value for Q3 2025.

  • Quarterly Raw Materials fell 59.6% to $446000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $446000.0 through Sep 2025, down 59.6% year-over-year, with the annual reading at $1.1 million for FY2025, 0.45% changed from the prior year.
  • Raw Materials for Q3 2025 was $446000.0 at IGC Pharma, down from $1.1 million in the prior quarter.
  • The five-year high for Raw Materials was $3.0 million in Q4 2022, with the low at $446000.0 in Q3 2025.
  • Average Raw Materials over 5 years is $1.8 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Raw Materials soared 910.57% in 2021, then crashed 59.6% in 2025.
  • Over 5 years, Raw Materials stood at $2.3 million in 2021, then skyrocketed by 30.5% to $3.0 million in 2022, then crashed by 53.52% to $1.4 million in 2023, then decreased by 24.4% to $1.1 million in 2024, then crashed by 58.28% to $446000.0 in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $446000.0, $1.1 million, and $1.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.